Regulation of leukemic cell differentiation and retinoid-induced gene expression by statins

Molecular Cancer Therapeutics

Volumn 8, Issue 3, 2009, Pages 615-625

  Sassano, Antonella ^a   Iacono, Marco Lo ^b   Antico, Giovanni ^a   Jordan, Alison ^a   Uddin, Shahab ^c   Calogero, Raffaele A ^b   Platanias, Leonidas C ^a  

^a NORTHWESTERN UNIVERSITY   (United States)

^b UNIVERSITY OF TURIN   (Italy)

^c KING FAISAL SPECIALIST HOSPITAL AND RESEARCH CENTER   (Saudi Arabia)

Author keywords

[No Author keywords available]

Indexed keywords

ANTHRA[1,9 CD]PYRAZOL 6(2H) ONE; ATORVASTATIN; FLUINDOSTATIN; HYDROXYMETHYLGLUTARYL COENZYME A REDUCTASE INHIBITOR; MITOGEN ACTIVATED PROTEIN KINASE KINASE 4; RETINOIC ACID; ANTINEOPLASTIC AGENT; HEPTANOIC ACID DERIVATIVE; PYRROLE DERIVATIVE; RETINOID;

ADJUVANT THERAPY; ANTINEOPLASTIC ACTIVITY; ARTICLE; CELL DIFFERENTIATION; CONTROLLED STUDY; ENZYME ACTIVATION; GENE EXPRESSION; GENETIC TRANSCRIPTION; HUMAN; HUMAN CELL; LEUKEMIA CELL; MYELOID LEUKEMIA; PRIORITY JOURNAL; DNA MICROARRAY; DRUG EFFECT; DRUG POTENTIATION; GENE EXPRESSION PROFILING; GENE EXPRESSION REGULATION; GENE REGULATORY NETWORK; GENETICS; LEUKEMIA; PATHOLOGY; TIME; TUMOR CELL CULTURE;

ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; CELL DIFFERENTIATION; DRUG SYNERGISM; GENE EXPRESSION PROFILING; GENE EXPRESSION REGULATION, LEUKEMIC; GENE REGULATORY NETWORKS; HEPTANOIC ACIDS; HUMANS; HYDROXYMETHYLGLUTARYL-COA REDUCTASE INHIBITORS; LEUKEMIA; OLIGONUCLEOTIDE ARRAY SEQUENCE ANALYSIS; PYRROLES; RETINOIDS; TIME FACTORS; TRETINOIN; TUMOR CELLS, CULTURED;

EID: 66449106631     PISSN: 15357163     EISSN: None     Source Type: Journal    
DOI: 10.1158/1535-7163.MCT-08-1196     Document Type: Article

References (50)

1. Goldstein JL, Brown MS. Regulation of the mevalonate pathway. Nature 1990;343:425-430 (Pubitemid 20065229)
2. Istvan ES, Deisenhofer J. Structural mechanism for statin inhibition of HMG-CoA reductase. Science 2001;292:1160-1164 (Pubitemid 32440937)
3. Ness GC, Zhao Z, Lopez D. Inhibitors of cholesterol biosynthesis increase hepatic low-density lipoprotein receptor protein degradation. Arch Biochem Biophys 1996;325:242-248 (Pubitemid 26025994)
4. Sacks FM, Pfeffer MA, Moye LA, et al. Cholesterol and recurrent Events Trial investigators. The effect of pravastatin on coronary events after myocardial infarction in patients with average cholesterol levels. N Engl J Med 1996;335:1001-1009
5. [No Authors Listed] The long-term intervention with pravastatin in ischaemic disease (LIPID) study group. Prevention of cardiovascular events and death with pravastatin in patients with coronary heart disease and a broad range of initial cholesterol levels. N Engl J Med 1998;339:1349-1357
6. Nissen SE, Tuzcu EM, Schoenhagen P, et al. Effect of intensive compared with moderate lipid-lowering therapy on progression of coronary atherosclerosis: a randomized controlled trial. JAMA 2004;291:1071-1080 (Pubitemid 38541684)
7. LaRosa JC, Grundy SM, Waters DD, et al. Intensive lipid lowering with atorvastatin in patients with stable coronary disease. N Engl J Med 2005;352:1425-1435 (Pubitemid 40471450)
8. Ballantyne CM, Bertolami M, Hernandez Garcia HR, et al. Achieving LDL cholesterol, non-HDL cholesterol, and apolipoprotein B target levels in high-risk patients: measuring effective reductions in cholesterol using rosuvastatin therapy (MERCURY) II. Am Heart J 2006;151:975 e1-9.
9. Rackley CE. Monotherapy with HMG-CoA reductase inhibitors and secondary prevention in coronary artery disease. Clin Cardiol 1996;19:683-689 (Pubitemid 26296800)
10. Chan KK, Oza AM, Siu LL. The statins as anticancer agents [review]. Clin Cancer Res 2003;9:10-19
11. Andela VB, Pirri M, Schwarz EM, et al. The mevalonate synthesis pathway as a therapeutic target in cancer [review]. Clin Orthop Relat Res 2003;415 Suppl:S59-66.
12. Brower V. Of cancer and cholesterol: studies elucidate anticancer mechanisms of statins. J Natl Cancer Inst 2003;95:844-846 (Pubitemid 36833868)
13. Demierre MF, Higgins PD, Gruber SB, Hawk E, Lippman SM. Statins and cancer prevention. Nat Rev Cancer 2005;5:930-942
14. Sassano A, Platanias LC. Statins in tumor suppression. Cancer Lett 2008;260:11-19
15. Kornblau SM, Banker DE, Stirewalt D, et al. Blockade of adaptive defensive changes in cholesterol uptake and synthesis in AML by the addition of pravastatin to idarubicin + high-dose Ara-C: a phase 1 study. Blood 2007;109:2999-3006. (Pubitemid 46482100)
16. Wu J, Wong WW, Khosravi F, Minden MD, Penn LZ. Blocking the Raf/MEK/ERK pathway sensitizes acute myelogenous leukemia cells to lovastatin-induced apoptosis. Cancer Res 2004;64:6461-6468 (Pubitemid 39297901)
17. Dimitroulakos J, Nohynek D, Backway KL, et al. Increased sensitivity of acute myeloid leukemias to lovastatin-induced apoptosis: a potential therapeutic approach. Blood 1999;93:1308-1318 (Pubitemid 29076146)
18. Li HY, Appelbaum FR, Willman CL, Zager RA, Banker DE. Cholesterol-modulating agents kill acute myeloid leukemia cells and sensitize them to therapeutics by blocking adaptive cholesterol responses. Blood 2003;101:3628-3634
19. Xia Z, Tan MM, Wong WW, Dimitroulakos J, Minden MD, Penn LZ. Blocking protein geranylgeranylation is essential for lovastatin-induced apoptosis of human acute myeloid leukemia cells. Leukemia 2001;15:1398-1407 (Pubitemid 32785309)
20. Banker DE, Mayer SJ, Li HY, William CL, Appelbaum FR, Zager RA. Cholesterol synthesis and import contribute to protective cholesterol increments in acute myeloid leukemia cells. Blood 2004;104:1816-1824 (Pubitemid 39202292)
21. Winandy S, Wu P, Georgopoulos K. A dominant mutation in the Ikaros gene leads to rapid development of leukemia and lymphoma. Cell 1995;83:289-299
22. Loeper S, Asa SL, Ezzat S. Ikaros modulates cholesterol uptake: a link between tumor suppression and differentiation. Cancer Res 2008;68:3715-3723
23. Dimitroulakos J, Thai S, Wasfy GH, Hedley DW, Minden MD, Penn LZ. Lovastatin induces a pronounced differentiation response in acute myeloid leukemias. Leuk Lymphoma 2000;40:167-178
24. Sassano A, Katsoulidis E, Antico G, et al. Suppressive effects of statins on acute promyelocytic leukemia cells. Cancer Res 2007;67:4524-4532 (Pubitemid 46815104)
25. Dermime S, Grignani F, Clerici M, et al. Occurrence of resistance to retinoic acid in the acute promyelocytic leukemia cell line NB4 is associated with altered expression of the PML/RARα protein. Blood 1993;82:1573-1577 (Pubitemid 23263975)
26. Uddin S, Yenush L, Sun XJ, et al. Interferon-α engages the insulin receptor substrate-1 to associate with the phosphatidylinositol 3′-kinase. J Biol Chem 1995;270:15938-15941
27. Verma A, Mohindru M, Deb DK, et al. Activation of Rac1 and the p38 mitogen-activated protein kinase pathway in response to arsenic trioxide. J Biol Chem 2002;277:44988-44995 (Pubitemid 36159097)
28. Alsayed Y, Uddin S, Mahmud N, et al. Activation of Rac1 and the p38 mitogen-activated protein kinase pathway in response to all-trans-retinoic acid. J Biol Chem 2001;276:4012-4019 (Pubitemid 37371483)
29. Gentleman RC, Carey VJ, Bates DM, et al. Bioconductor: open software development for computational biology and bioinformatics. Genome Biol 2004;5:R80.
30. Bolstad BM, Irizarry RA, Astrand M, Speed TP. A comparison of normalization methods for high density oligonucleotide array data based on variance and bias. Bioinformatics 2003;19:185-193 (Pubitemid 36181903)
31. Conesa A, Nueda MJ, Ferrer A, Talon M. maSigPro: a method to identify significantly differential expression profiles in time-course microarray experiments. Bioinformatics 2006;22:1096-1102
32. Haslett JN, Sanoudou D, Kho AT, et al. Gene expression comparison of biopsies from Duchenne muscular dystrophy (DMD) and normal skeletal muscle. Proc Natl Acad Sci U S A 2002;99:15000-15005 (Pubitemid 35334599)
33. Livak KJ, Schmittgen TD. Analysis of relative gene expression data using real-time quantitative PCR and the 2(-ΔΔC(T)) Method. Methods 2001;25:402-408 (Pubitemid 34164012)
34. Dickens M, Rogers JS, Cavanagh J. A cytoplasmic inhibitor of the JNK signal transduction pathway. Science 1997;277:693-696 (Pubitemid 27373916)
35. Bonny C, Oberson A, Negri S, Sauser C, Schorderet DF. Cell-permeable peptide inhibitors of JNK: novel blockers of β-cell death. Diabetes 2001;50:77-82. (Pubitemid 32047984)
36. Barr RK, Kendrick TS, Bogoyevitch MA. Identification of the critical features of a small peptide inhibitor of JNK activity. J Biol Chem 2002;277:10987-10997 (Pubitemid 34952855)
37. Raychaudhuri S, Stuart JM, Altman RB. Principal components analysis to summarize microarray experiments: application to sporulation time series. Pacific Symp Biocomput 2000;452-463
38. Warrell RP, Jr., de The H, Wang ZY, Degos L. Acute promyelocytic leukemia. N Engl J Med 1993;329:177-189 (Pubitemid 23195739)
39. Borrow J, Goddard AD, Sheer D, Solomon E. Molecular analysis of acute promyelocytic leukemia breakpoint cluster region on chromosome 17. Science 1990;249:1577-1580 (Pubitemid 20341939)
40. Melnick A, Licht JD. Deconstructing a disease: RARα, its fusion partners, and their roles in the pathogenesis of acute promyelocytic leukemia. Blood 1999;93:3167-3215 (Pubitemid 29220886)
41. Tallman MS, Nabhan C, Feusner JH, Rowe JM. Acute promyelocytic leukemia: evolving therapeutic strategies. Blood 2002;99:759-767 (Pubitemid 34525534)
42. Miller WH, Jr., Waxman S. Differentiation induction as a treatment for hematologic malignancies. Oncogene 2002;21:3496-3506 (Pubitemid 34587718)
43. Kambhampati S, Verma A, Li Y, Parmar S, Sassano A, Platanias LC. Signaling pathways activated by all-trans-retinoic acid in acute promyelocytic leukemia cells. Leuk Lymphoma 2004;45:2175-2185 (Pubitemid 39504311)
44. Douer D, Tallman MS. Arsenic trioxide: new clinical experience with an old medication in hematologic malignancies. J Clin Oncol 2005;23:2396-2410 (Pubitemid 46218734)
45. Liesveld JL, Harbol AW, Belanger T, Rosell KE, Abboud CN. MIP-1α and TGF-β production in CD34+ progenitor-stromal cell coculture systems: effects of progenitor isolation method and cell-cell contact. Blood Cells Mol Dis 2000;26:261-275
46. Jing H, Yen JH, Ganea D. A novel signaling pathway mediates the inhibition of CCL3/4 expression by prostaglandin E2. J Biol Chem 2004;279:55176-55186 (Pubitemid 40066512)
47. Dinarello CA. Biologic basis for interleukin-1 in disease. Blood 1996;87:2095-2147 (Pubitemid 26086851)
48. Tirone F. The gene PC3 (TIS21/BTG2), prototype member of the PC3/BTG/TOB family: regulator in control of cell growth, differentiation, and DNA repair? J Cell Physiol 2001;187:155-165
49. Passeri D, Marcucci A, Rizzo G, et al. Btg2 enhances retinoic acid-induced differentiation by modulating histone H4 methylation and acetylation. Mol Cell Biol 2006;26:5023-5032 (Pubitemid 43955816)
50. Lindsey S, Huang W, Wang H, Horvath E, Zhu C, Eklund EA. Activation of SHP2 protein-tyrosine phosphatase increases HoxA10-induced repression of the genes encoding gp91(PHOX) and p67(PHOX). J Biol Chem 2007;282:2237-2249 (Pubitemid 47076743)